He was diagnosed years ago with a handful of autoimmune conditions, treating them with drugs like Abbvie's Humira, which he helped commercialize.
CVS Health's decision to remove Lilly's Jardiance for J&J's Invokana has analysts wondering if exclusive pricing contracts could shape the future of the GLP-1 class.
Two recent cash infusions suggest investors are bullish on point-of-care advertising. Is the channel ready for its moment in the spotlight?
The agency appointed Sonja Foster-Storch, previously president of McCann Echo, to fill a role that has been vacant since 2016.
Business analysts have generally agreed that WPP's half-year earnings fell below expectations given recent market commentary, but have offered mixed guidance going forward.
Novartis launches MS study with Apple's ResearchKit; the FDA considering limiting risk info in drug ads; J&J loses baby powder lawsuit
She is leading commercial partnerships for the point-of-care company.
The FDA approves Ironwood's gout drug; GSW names new president; Samsung and Takeda to partner on biologic development
Procter & Gamble has revived the campaign with a new spot tackling the lack of confidence during puberty.
WPP was added to Sanofi's creative agency roster and GroupM's Mindshare is the drugmaker's new global media agency of record.
Lawmakers to investigate pricing of MS drugs; Mylan will pay $465 million to resolve EpiPen allegations; the FDA approves Pfizer's new cancer drug
Express Scripts to limit opioid coverage; Novo's diabetes drug lowers glucose levels in trial; startup aims to give doctors access to a patient's total costs
The lobbying group said it's unclear what the agency's goal is with this research and how it promotes public health.
Prescription rates dramatically decreased following the price hikes of Valeant's Isuprel and Nitropress in 47 hospitals.
Johnson & Johnson has breached the U.K.'s drug regulation code in three places in promotions for smoking cessation product Nicorette.
Gottlieb criticizes drugmakers for 'gaming the system' on generics; investors ignore Trump's pharma criticism; docs are more supportive of single payer
Both positions were newly created as the agency has grown over the past year.
It's not often that pharmaceutical companies are held up as examples of morality or leadership to the general public.